PURPOSE: To investigate the prevalence of non-alcoholic fatty liver disease (NAFLD) assessed by the fatty liver index (FLI), in lower urinary tract symptoms (LUTS) patients and to estimate its ability in predicting LUTS. METHODS: We performed a cross-sectional analysis of 448 consecutive patients affected by LUTS. LUTS were evaluated using the IPSS questionnaire and metabolic syndrome (MetS) criteria (by International Diabetes Federation). FLI, prostate volume (PV), serum prostate-specific antigen, total testosterone (TT) and homeostasis model assessment (HOMA) index were evaluated. A value of FLI ≥40 was set to predict NAFLD. Patients were divided into Group A (FLI <40) and Group B (FLI ≥40). Odds ratios (OR) for having moderate-severe LUTS were calculated. Logistic regression model was fitted adjusting for confounding factors. RESULTS: Group B showed higher prevalence of MetS, IR, moderate-severe LUTS and ED, higher IPSS, IPSS-storage, IPSS-voiding, total prostate volume, insulin, HOMA and lower TT and IIEF-5. Univariate logistic regression analysis demonstrated that continuous FLI (OR = 1.03, p < 0.05) and FLI ≥40 (OR = 2.41, p < 0.01) significantly increase the risk of moderate-severe LUTS. Continuous FLI (OR = 1.12, p < 0.01) and FLI ≥40 (OR = 5.39, p < 0.01) were independent predictors of moderate-severe LUTS at the multivariate logistic regression analysis, after adjusting for confounding factors. Subjects with MetS and FLI ≥40 had 2.0-fold the risk of moderate-severe LUTS (OR = 2.10, p < 0.01). CONCLUSIONS: Non-alcoholic fatty liver disease (NAFLD) subjects have higher risk of LUTS. The presence of FLI ≥40 can be used to predict subjects at high risk of LUTS.
PURPOSE: To investigate the prevalence of non-alcoholic fatty liver disease (NAFLD) assessed by the fatty liver index (FLI), in lower urinary tract symptoms (LUTS) patients and to estimate its ability in predicting LUTS. METHODS: We performed a cross-sectional analysis of 448 consecutive patients affected by LUTS. LUTS were evaluated using the IPSS questionnaire and metabolic syndrome (MetS) criteria (by International Diabetes Federation). FLI, prostate volume (PV), serum prostate-specific antigen, total testosterone (TT) and homeostasis model assessment (HOMA) index were evaluated. A value of FLI ≥40 was set to predict NAFLD. Patients were divided into Group A (FLI <40) and Group B (FLI ≥40). Odds ratios (OR) for having moderate-severe LUTS were calculated. Logistic regression model was fitted adjusting for confounding factors. RESULTS: Group B showed higher prevalence of MetS, IR, moderate-severe LUTS and ED, higher IPSS, IPSS-storage, IPSS-voiding, total prostate volume, insulin, HOMA and lower TT and IIEF-5. Univariate logistic regression analysis demonstrated that continuous FLI (OR = 1.03, p < 0.05) and FLI ≥40 (OR = 2.41, p < 0.01) significantly increase the risk of moderate-severe LUTS. Continuous FLI (OR = 1.12, p < 0.01) and FLI ≥40 (OR = 5.39, p < 0.01) were independent predictors of moderate-severe LUTS at the multivariate logistic regression analysis, after adjusting for confounding factors. Subjects with MetS and FLI ≥40 had 2.0-fold the risk of moderate-severe LUTS (OR = 2.10, p < 0.01). CONCLUSIONS:Non-alcoholic fatty liver disease (NAFLD) subjects have higher risk of LUTS. The presence of FLI ≥40 can be used to predict subjects at high risk of LUTS.
Authors: Giuseppe Morgia; Sebastiano Cimino; Vincenzo Favilla; Giorgio Ivan Russo; Francesco Squadrito; Giuseppe Mucciardi; Lorenzo Masieri; Letteria Minutoli; Giuseppe Grosso; Tommaso Castelli Journal: Int Braz J Urol Date: 2013 Mar-Apr Impact factor: 1.541
Authors: C Couillard; J Gagnon; J Bergeron; A S Leon; D C Rao; J S Skinner; J H Wilmore; J P Després; C Bouchard Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Giorgio Ivan Russo; Sebastiano Cimino; Eugenia Fragalà; Salvatore Privitera; Sandro La Vignera; Rosita Condorelli; Aldo E Calogero; Tommaso Castelli; Vincenzo Favilla; Giuseppe Morgia Journal: J Sex Med Date: 2014-05-19 Impact factor: 3.802
Authors: Francesco Lotti; Giovanni Corona; Linda Vignozzi; Matteo Rossi; Elisa Maseroli; Sarah Cipriani; Mauro Gacci; Gianni Forti; Mario Maggi Journal: Asian J Androl Date: 2014 Mar-Apr Impact factor: 3.285
Authors: S Cimino; S Voce; F Palmieri; V Favilla; T Castelli; S Privitera; R Giardina; G Reale; G I Russo; G Morgia Journal: Int J Impot Res Date: 2017-08-17 Impact factor: 2.896
Authors: V Favilla; G I Russo; G Reale; S Leone; T Castelli; S La Vignera; R A Condorelli; A E Calogero; S Cimino; G Morgia Journal: Int J Impot Res Date: 2015-07-30 Impact factor: 2.896
Authors: Aleksandra Rył; Iwona Rotter; Tomasz Miazgowski; Marcin Słojewski; Barbara Dołęgowska; Anna Lubkowska; Maria Laszczyńska Journal: Diabetol Metab Syndr Date: 2015-10-29 Impact factor: 3.320
Authors: Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Min Sun Kwak; Jong In Yang; Boram Park; Seong Joon An; Joo Sung Kim Journal: J Korean Med Sci Date: 2020-06-08 Impact factor: 2.153
Authors: Giorgio Ivan Russo; Gaetano Larganà; Arcangelo Sebastianelli; Andrea Cocci; Marina Di Mauro; Ilenia Rapallo; Giuseppe Morgia; Matteo Mario Morgia; Sandro La Vignera; Rosita Condorelli; Aldo E Calogero; Iacopo Olivotto; Simone Morselli; Sergio Serni; Mauro Gacci Journal: J Clin Med Date: 2021-01-22 Impact factor: 4.241
Authors: Asma Omran; Bianca M Leca; Eduard Oštarijaš; Natasha Graham; Ana Sofia Da Silva; Zoulikha M Zaïr; Alexander D Miras; Carel W le Roux; Royce P Vincent; Linda Cardozo; Georgios K Dimitriadis Journal: Ther Adv Endocrinol Metab Date: 2021-12-08 Impact factor: 3.565